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Background: Antidepressants, which are widely used for treatment of chronic pain, are thought to have
antinociceptive effects by blockade of serotonin and noradrenaline reuptake. However, these drugs also interact
with various receptors such as excitatory glutamatergic receptors. Thermal hyperalgesia was induced by intrathecal
injection of NMDA in rats. Paw withdrawal latency was measured after intrathecal injection of antidepressants. The
effects of antidepressants on the NMDA and AMPA-induced responses were examined in lamina II neurons of rat
spinal cord slices using the whole-cell patch-clamp technique. The effects of milnacipran followed by application of
NMDA on pERK activation were also investigated in the spinal cord.
Results: Intrathecal injection of milnacipran (0.1 μmol), but not citalopram (0.1 μmol) and desipramine (0.1 μmol),
followed by intrathecal injection of NMDA (1 μg) suppressed thermal hyperalgesia. Milnacipran (100 μM) reduced
the amplitude of NMDA (56 ± 3 %, 64 ± 5 % of control)-, but not AMPA (98 ± 5 %, 97 ± 5 % of control)-mediated
currents induced by exogenous application and dorsal root stimulation, respectively. Citalopram (100 μM) and
desipramine (30 μM) had no effect on the amplitude of exogenous NMDA-induced currents. The number of
pERK-positive neurons in the group treated with milnacipran (100 μM), but not citalopram (100 μM) or desipramine
(30 μM), followed by NMDA (100 μM) was significantly lower compared with the NMDA-alone group.
Conclusions: The antinociceptive effect of milnacipran may be dependent on the drug’s direct modulation of
NMDA receptors in the superficial dorsal horn. Furthermore, in addition to inhibiting the reuptake of monoamines,
glutamate NMDA receptors are also important for analgesia induced by milnacipran.
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It is well established that antidepressants have antinoci-
ceptive effects; because of this, they are widely used for
treatment of chronic pain [1]. In particular, tricyclic anti-
depressants (TCAs) have long been the mainstay of
treatment for neuropathic pain, which is due to lesion or
dysfunction of the peripheral or central nervous system.
Antidepressants have the unique ability to inhibit the
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reproduction in any medium, provided the orand noradrenaline (NA) at the neuronal terminals [2],
and this activity can produce antinociceptive effects. Re-
cently, more selective monoamine reuptake inhibitors,
such as 5-HT and NA reuptake inhibitors (SNRIs) and
selective 5-HT reuptake inhibitors (SSRIs), have been
introduced and are clinically used to treat neuropathic
pain [1]. However, the underlying mechanisms of these
drugs may be more complex than simply the blockade of
5-HT and NA reuptake.
In fact, TCAs could also interact with various recep-
tors including N-methyl-D-aspartate (NMDA) receptors
to produce nociceptive effects. NMDA glutamate recep-
tors are one of the major receptor channel types mediat-
ing rapid excitatory neurotransmission in the central
nervous system, and they also play an important role in
central sensitization regarding long-term pain [3,4].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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interactions in nociceptive transmission between TCAs
and NMDA receptors in the spinal cord [5]. However,
there have been no studies demonstrating that the anti-
nociceptive effects of antidepressants are attributable to
the inhibition of NMDA receptors in the spinal cord at
the cellular level.
The spinal cord is an important site of action of
antidepressant-mediated antinociception [6]. The
brainstem-spinal descending 5-HT and NA systems sup-
press nociceptive signals from primary afferent neurons
to the spinal dorsal horn. Concurrently, the superficial
dorsal horn preferentially receives nociceptive primary
afferent fibers. Thus, the spinal dorsal horn is thought to
play an important role in modulating nociceptive trans-
mission from the periphery [7,8] as well as in regulating
the antinociceptive effect of antidepressants.
The purpose of the current study was to test the hy-
pothesis that 3 different antidepressants, milnacipran as
a SNRI, citalopram as a SSRI, and desipramine as a TCA
(a preferential noradrenergic reuptake inhibitor) have a
direct antagonistic effect on NMDA and AMPA-
mediated responses in the spinal dorsal horn.
Methods
Surgical Preparation
The study was approved by the Animal Care and Use
Committee of the Gunma University School of Medicine
(Maebashi, Japan). Male rats (250–270 g) were used in all
experiments. Animals were housed under a 12-h light–
dark cycle with food and water ad libitum. For intrathecal
administration, a sterilized 32-gauge polyethylene catheter
(ReCathCo, Allison Park, PA) connected to an 8.5-cm
Tygon external tubing (Saint-Gobain Performance Plas-
tics, Akron, OH) was inserted under isoflurane anesthesia,
as previously described [9]. The catheter was passed caud-
ally 8.0 cm from the cisterna magnum to the lumbar en-
largement. The animals were allowed to recover for
1 week before being used experimentally. Only animals
without evidence of neurologic dysfunction after catheter
insertion were used for all studies.
Testing Procedures
The thermal nociceptive threshold was measured with a
device (Plantar Test®, IITC Inc. Life Science, Woodland
Hills, CA) using a method similar to that reported previ-
ously [10]. Rats were placed in individual plastic boxes
(10 × 20 × 24 cm) on the glass surface of the testing ap-
paratus, which was maintained at 30 °C during all testing,
and were allowed to acclimate for 30 min. Paw with-
drawal latency (PWL) was determined using an intense
light focused on the hind paw, as previously described
[10]. Light intensity was adjusted so that baseline latency
was between 9 and 11 s in all animals. A cutoff of 20 swas selected to avoid tissue damage during periods of an-
algesia, but no animals reached this cutoff point.
The thermal hyperalgesic state was induced by intra-
thecal injection of 1 μg NMDA. The dose was selected
according to a previous study [11]. This experiment is
most specific to evaluate the effect of antidepressants on
NMDA-mediated responses in the spinal cord. PWL was
measured three times in the right or left foot in the mid-
dle of the footpad. These three observations were aver-
aged for each animal. PWLs were measured before and
after intrathecal injection of milnacipran, citalopram,
desipramine, or saline (six animals in each group), and
NMDA was injected intrathecally 15 min after the injec-
tion (time 0). PWLs were measured at 0, 30, 60, 90, and
120 min after intrathecal injection of NMDA.
Drugs and Their Administration
The agents administered in this study were milnacipran,
citalopram, desipramine, and NMDA. Each antidepressant
or saline was administered intrathecally 15 min prior to
NMDA injection. Drugs were administered intrathecally
in a volume of 5 μl, followed by an injection of 10 μl of sa-
line to flush the catheter. All drugs were dissolved in nor-
mal saline. The doses of milnacipran were selected
according to the previous studies [12,13]. The maximum
dose of milnacipran (0.1 μmol) was used for desipramine
and citalopram injections because the doses to produce
analgesia in these 3 drugs are almost same [14,15].
In Vitro Patch-Clamp Recordings
This portion of the study was approved by the Animal
Care and Use Committee at Niigata University Graduate
School of Medical and Dental Sciences (Niigata, Japan).
Male rats (150–200 g) were anesthetized with urethane
(1.5 g/kg, i.p.). A dorsal laminectomy was performed, and
the lumbosacral segment of the spinal cord with ventral
and dorsal roots attached was removed [16,17]. The rats
were then immediately killed by exsanguination, and the
spinal cords were placed in pre-oxygenated ice-cold Krebs
solution. After the arachnoid membrane was removed, the
spinal cord was placed in an agar block and mounted on a
metal stage. A transverse slice (500-μm thick) with an
attached dorsal root was cut on a DTK-1500 Microslicer
(Dosaka, Kyoto, Japan) and placed on a nylon mesh in the
recording chamber. The slice was perfused continuously
with Krebs solution (10 ml/min) equilibrated with a 95 %
O2 and 5 % CO2 gas mixture at 36°C. The Krebs solution
contained (in mM): NaCl, 117; KCl, 3.6; CaCl2, 2.5; MgCl2,
1.2; NaH2PO4, 1.2; NaHCO3, 25; and D-glucose, 11.5.
Whole-cell patch-clamp recordings were made from lam-
ina II neurons in voltage-clamp mode using patch pipette
electrodes having a resistance of 10 MΩ. The patch pip-
ette solution contained (in mM): Cs-sulfate, 110; CaCl2,
0.5; MgCl2, 2; EGTA, 5; HEPES, 5; tetraethylammonium
Kohno et al. Molecular Pain 2012, 8:45 Page 3 of 9
http://www.molecularpain.com/content/8/1/45(TEA), 5; and ATP-Mg salt, 5. Signals were amplified
using an Axopatch 200B amplifier (Molecular Devices,
Union City, CA) and were low-pass filtered with a 2-kHz
cutoff and digitized at 5 kHz. Data were collected and ana-
lyzed using pClamp 10.0 software (Molecular Devices). All
experiments were performed in voltage-clamp mode at a
holding potential of −40 mV for recording exogenous
NMDA current and −70 mV for recording exogenous
AMPA current. To test the synaptic response, NMDA
receptor-mediated excitatory postsynaptic currents
(EPSCs) were observed by dorsal root electrical stimula-
tion at +40 mV in the presence of an AMPA/kainate re-
ceptor antagonist (6-cyano-7-nitroquinoxaline-2, 3-dione,
CNQX; 10 μM), a GABAA receptor antagonist (bicucul-
line; 20 μM), and a glycine receptor antagonist (strych-
nine; 1 μM). AMPA receptor-mediated EPSCs were
observed by dorsal root stimulation at −70 mV. Evoked
EPSCs that displayed a constant latency and lack of fail-
ures with high frequency stimulation (20 Hz) were classi-
fied as monosynaptic. Drugs were applied by superfusion
without alteration of the perfusion rate and temperature.
NMDA (100 μM) and AMPA (10 μM) were applied to
slices for 30 s, and each antidepressant was applied to
slices for 3 min. Peak NMDA and AMPA currents were
measured before and after each treatment and expressed
as (posttreatment/pretreatment) × 100 (as percentages).Immunohistochemistry
The spinal cord slices (700 μm) from male rats (150–
250 g) were perfused with Krebs solution for at least 3 h
before application of drugs. Milnacipran (100 μM) was
applied for 10 min before NMDA stimulation (100 μM
for 5 min) and was present during NMDA stimulation.
After drug treatment, the slices were fixed in 4 % paraf-
ormaldehyde for 60 min, replaced with sucrose over-
night, cut in a cryostat at a thickness of 16 μm, and
mounted on slide glass. Phosphorylated extracellular
signal-regulated kinase 1/2 (pERK1/2) was visualized by
indirect immunohistochemistry [18]. Sections were incu-
bated with rabbit anti-pERK1/2 antibody (Cell Signaling
Technology, Danvers, MA; 1:1000) for 2 days at 4 °C.
The sections were incubated with biotinylated anti-
rabbit secondary antibody (Vector Laboratories, Burlin-
game, CA; 1:400) for 4 h at room temperature. Signals
were visualized with Vectastain ABC systems (Vector
Laboratories) following the manufacturer’s instruction.
Signals were analyzed under a microscope-digital cam-
era system (Nikon, Tokyo, Japan). Experimenters who
were unaware of the experimental protocol counted cells
in a blinded manner. At least five nonadjacent sections
were randomly selected for cell count. The number of
pERK1/2-positive neurons in the superficial dorsal horn
from each of five sections was averaged for each animal.Preparation of Drugs
The drugs used in this study were milnacipran, citalo-
pram, desipramine (provided by Asahi Kasei Corporation,
Osaka, Japan), NMDA, AMPA, CNQX, bicuculline,
strychnine, WAY100635 maleate salt (Sigma-Aldrich, St.
Louis, MO) and tetrodotoxin (TTX), yohimbine hydro-
chloride (Wako, Osaka, Japan). Citalopram and bicucul-
line were first dissolved in dimethyl sulphoxide (DMSO)
at 1000 times the concentrations to be used. The other
drugs were first dissolved in distilled water at 1000 times
the concentrations to be used, and then these drugs were
diluted to the final concentration in Krebs solution imme-
diately before use.
Statistical Analysis
Data are expressed as means ± SEM. Statistical signifi-
cance was determined as P< 0.05 using either the Stu-
dent’s paired t-test or a two-way analysis of variance
(ANOVA), followed by a Student-Newman-Keuls post
hoc test for multiple comparisons.
Results
Milnacipran Suppresses NMDA-Induced Thermal
Hyperalgesia
Intrathecal injection of saline or each antidepressant alone
did not alter PWL (data not shown). Intrathecal injection
of 1 μg NMDA 30 min after saline injection produced
thermal hyperalgesia 30 min after the NMDA injection
compared with the pre-value (9.87± 0.89 to 6.13± 0.89 s,
P< 0.01). Mechanical allodynia was not induced by intra-
thecal injection of NMDA. Although the hyperalgesia
induced by intrathecal administration of NMDA is a rapid
and transient in a tail-flick test [19], the reduction in PWL
continued up to 120 min after NMDA injection in the
present study (saline group, Figure 1). Intrathecal injection
of milnacipran followed by intrathecal injection of NMDA
suppressed thermal hyperalgesia in a dose-dependent
manner at doses from 0.01 to 0.1 μmol (P< 0.05 by two-
way ANOVA, Figure. 1A). In contrast, citalopram
(0.1 μmol) did not inhibit thermal hyperalgesia during the
testing period (P=0.25 by two-way ANOVA; Figure 1B).
Similarly, desipramine (0.1 μmol) did not suppress
NMDA-induced thermal hyperalgesia (P=0.62 by two-
way ANOVA, Figure 1C).
Milnacipran Inhibits NMDA, but not AMPA Receptor-
Mediated Responses in Dorsal Horn Neurons
To study the effects of milnacipran on excitatory syn-
aptic transmission, whole-cell patch-clamp recordings
were made from rat lamina II neurons. Milnacipran did
not alter the level of holding current required to main-
tain neurons at −40 mV and −70 mV, respectively. Mil-
nacipran had no effect on the amplitude (102 ± 5 % of
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Figure 1 Milnacipran suppresses NMDA-induced thermal
hyperalgesia (B) or desipramine+NMDA (C) on the paw
withdrawal latency against thermal nociceptive stimuli. Thermal
hyperalgesia was induced by intrathecal injection of NMDA. Saline
or each drug was injected 15 min before NMDA. Paw withdrawal
latencies are expressed as mean ± SEM for six rats in each group. *
P< 0.05 compared with saline-treated group at each time point by
a Student-Newman-Keuls post hoc after two-way ANOVA.
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mV. Exogenous application of NMDA (100 μM, 30 s,
at −40 mV) elicited an inward current in neurons
(Figure 2A, C), reflecting the activation of NMDA
receptors. To confirm that NMDA-induced currents
were postsynaptic phenomena, we examined the cur-

























































Figure 2 (A) Milnacipran inhibits the response to exogenous
NMDA. Milnacipran reversibly inhibited NMDA-induced currents. In
this figure and subsequent figures, the horizontal bars above the
chart recordings indicate the duration of drug superfusion. (B) The
relative amplitudes were shown in the presence of milnacipran. **
P< 0.01, * P< 0.05 (C) Neither citalopram nor desipramine affected
the amplitudes of NMDA-induced currents. (D) Comparison of the
NMDA-induced currents in control and in the presence of
citalopram or desipramine.
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neurons. Since TTX (0.5 μM) did not affect the
amplitudes of NMDA-induced currents (103 ± 4 % of
control, n = 5; P = 0.84; data not shown), the currents
were exclusively postsynaptic. Therefore, the follow-
ing experiments were done in the absence of TTX.
Pre-application of milnacipran (100 μM) for 3 min
reduced the amplitudes of NMDA-induced currents
to 56 ± 3 % (n = 10, P< 0.01; Fig. 2A, B) of the con-
trol values. These effects of milnacipran were revers-
ible, and the amplitudes of currents recovered to the
control values within 5–10 min (Figure 2A). At a
lower concentration of 10 or 30 μM, milnacipran also
decreased NMDA-induced currents (80 ± 4 % of the
control, n = 5, P< 0.01; 71 ± 8 % of the control, n = 6,





























Figure 3 (A) Milnacipran does not inhibit AMPA receptor-mediated re
induced currents. (B) Representative traces of dorsal root stimulation evoke
EPSCs were recorded at +40 mV. AMPA-mediated EPSCs were recorded at
but not AMPA-mediated EPSCs. (C) Comparison of the NMDA- and AMPA-
P< 0.01.the observed effects were specific for milnacipran, we
examined other antidepressants; i.e., citalopram and
desipramine. Pre-application of citalopram (100 μM)
for 3 min failed to reduce the amplitudes of NMDA-
induced currents (100 ± 5 % of control, n = 5, P= 0.96;
Figure 2C, D). Pre-application of desipramine (30 μM)
for 3 min also failed to reduce the amplitudes of
NMDA-induced currents (98 ± 4 % of control, n = 5,
P= 0.57; Figure 2C, D). In contrast, milnacipran (100
μM) had no effect on the amplitudes of exogenously
applied AMPA (10 μM, 30 s, at −70 mV)-induced
currents (98 ± 5 % of control, n = 7, P= 0.63; Figure 3A).
These results suggest that milnacipran, but not the
other antidepressants, inhibited NMDA, but not














































sponses in dorsal horn neurons. Milnacipran did not inhibit AMPA-
d monosynaptic NMDA- and AMPA-mediated EPSCs. NMDA-mediated
−70 mV. Milnacipran reversibly decreased the amplitudes of NMDA-,
mediated EPSCs in control and in the presence of milnacipran. *
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amplitudes of dorsal root stimulation evoked EPSCs.
Milnacipran (100 μM) inhibited the amplitudes of
monosynaptic NMDA-mediated EPSCs to 64 ± 5 %
(n = 4, P< 0.01; Figure 3B, C) of the control values. In
contrast, milnacipran (100 μM) did not inhibit the
amplitudes of monosynaptic AMPA receptor-mediated
EPSCs (97 ± 5 % of control, n = 5, P= 0.62; Figure 3B, C).
To exclude the possibility that milnacipran inhibited the
amplitudes of NMDA-mediated EPSCs as a result of
the blockade of 5-HT and NA reuptake, we examined the
NMDA-mediated EPSCs in the presence of 5-HT1A re-
ceptor antagonist, WAY100635 (10 μM), and α2 receptor
antagonist, yohimbine (1 μM). The concentrations of
WAY100635 and yohimbine at the concentrations used
here are sufficiently high to block the 5-HT1A [20] and
α2 receptors [21], respectively. However, milnacipran
also inhibited the amplitudes of NMDA-mediated EPSCs
to 69 ± 8 % (n = 3, P< 0.01) of the control values.
Effects of Antidepressants on ERK Activation in the Spinal
Cord
The slice preparation offers a reliable condition under
which to study pERK expression [22,23]. In addition,
multiple slices can be prepared from each spinal cord
segment, and milnacipran can be applied in a known
condition in vitro. The slices were perfused for more
than 3 h before stimulation to reduce possible pERK
background caused by slice preparation [22,23]. There
were very few pERK-positive neurons noted in control
spinal cord slices (Figure 4).
In the present research, pERK-positive neurons were
occasionally observed in the control dorsal horn. Bath
application of NMDA (100 μM) for 5 min producedFigure 4 Effects of antidepressants on ERK activation in the spinal co
treatment with milnacipran compared with the NMDA-alone group, but no
neurons. NS = not significant.activation of pERK in the superficial dorsal horn
neurons. Distribution of NMDA-evoked pERK expres-
sion was similar to that of previous observations [22].
The number of pERK-positive neurons significantly
increased in the NMDA-treated group (P< 0.01 vs. con-
trol, Figure 4). The number of pERK-positive neurons in
the group treated with milnacipran (100 μM), but not
with citalopram (100 μM) or desipramine (30 μM) fol-
lowed by NMDA was significantly lower compared with
the NMDA-alone group (P< 0.05, Figure 4).
Discussion
We demonstrated that intrathecal administration of mil-
nacipran, but not citalopram or desipramine mediated an
inhibition of NMDA-induced thermal hyperalgesia. More-
over, we documented the inhibition of NMDA-mediated
currents by milnacipran, but not by citalopram or desipra-
mine in spinal lamina II. We also demonstrated that acti-
vation of pERK induced by NMDA was significantly
suppressed by milnacipran in dorsal horn neurons. Taken
together, these findings indicate that milnacipran has a
direct antinociceptive effect in the spinal cord through its
modulation of NMDA receptors.
Some investigators have reported interactions between
TCAs and NMDA receptors in nociceptive transmission.
Eisenach and Gebhart [5] reported that intrathecal ad-
ministration of amitriptyline reversed thermal hyperalge-
sia via NMDA receptor antagonism in a rat model of
inflammation. Kawamata et al. [24] also using the rat
model of inflammation, reported that intrathecally
injected desipramine produced analgesia unrelated to
NA reuptake inhibition. These reports suggest that
TCAs exert a direct inhibitory effect on NMDA recep-
tors to produce analgesia in the spinal cord. TCAs mayrd. ERK activation was significantly suppressed by simultaneous
t with citalopram or desipramine. Arrow indicates the pERK-positive
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interact with various receptors. It has been shown that
TCAs block sodium channels [25,26] as well as voltage-
dependent calcium channels [27,28] and that TCAs in-
hibit adenosine reuptake [29]. Further, most TCAs have
affinity for opioid [30], NA, 5-HT, histamine, and mus-
carinic acetylcholine receptors [31]. Therefore, these
various mechanisms of action of TCAs might contribute
to antinociceptive effects in some kinds of chronic pain
models.
Desipramine did not suppress NMDA-induced thermal
hyperalgesia in the present study. However, Hwang and
Wilcox [6] reported that desipramine was antinociceptive
in three nociceptive tests, tail-flick test, intrathecal sub-
stance P-induced behavioral test and intradermal hyper-
tonic saline-induced behavioral test. Moreover, they
indicated that the analgesic effect by desipramine probably
involves blockade of monoamine reuptake. This discrep-
ancy between our result and that of previous study is
likely to be due to different underlying mechanisms of
desipramine.
Although there is some evidence that TCAs block
NMDA receptor-mediated responses, the site of action
is controversial. Based on radioligand binding studies,
Reynolds and Miller [32] have suggested that TCAs act
at the Zn2+ recognition site on the NMDA receptor. Sills
and Loo [33] have reported that TCAs bind with higher
affinity to the phencyclidine binding site on the NMDA
receptor. Moreover, Sernagor et al. [34] have reported
that desipramine blocked NMDA-induced currents in
hippocampal neurons by acting on the open channel. In
contrast to TCAs, milnacipran has no relevant affinity
for any other receptors, including α-adrenergic, 5-HT,
histamine, muscarinic acetylcholine, opioid, or NMDA
receptors [35]. However, Shuto et al. [36] reported that
milnacipran (IC50 = 6.3 μM), is a class of noncompetitive
NMDA receptor antagonist, although the binding affin-
ity of milnacipran for the NMDA receptor is not strong.
Although there is no evidence that milnacipran binds to
the NMDA receptor, it is assumed that it may act at the
recognition site for Zn2+ or at the phencyclidine binding
site of the NMDA receptor. Further study is required to
clarify this point.
Milnacipran inhibits the presynaptic reuptake of monoa-
mines, 5-HT and NA with an IC50 of 100 to 200 nM,
respectively in the brain [37]. However, in this study, mil-
nacipran has the antagonistic effect on NMDA-mediated
responses in the spinal cord at a concentration of 10–100
μM. Some previous studies [32,36,38] indicate that TCAs
also inhibits the NMDA receptors in the brain at a concen-
tration of 10–100 μM. Therefore, it is likely that the con-
centration of inhibiting the NMDA receptors by
milnacipran is higher than that of inhibiting reuptake of
the monoamines.In the present study, milnacipran reduced the ampli-
tudes of exogenously applied NMDA-induced currents
in lamina II neurons. Moreover, milnacipran inhibited
the amplitudes of dorsal root stimulation evoked
NMDA-mediated EPSCs. There are no differences in
the degree of depression by milnacipran between
NMDA induced-current and dorsal root stimulation
evoked NMDA-mediated EPSCs. These results suggest
that synaptic and extra synaptic NMDA receptors in
dorsal horn neurons are similarly modulated by milna-
cipran. Moreover, milnacipran inhibited the amplitudes
of NMDA-mediated EPSCs in the presence of 5-HT
antagonist and α2 receptor antagonist. Therefore, it
is unlikely that an antagonistic effect of milnacipran on
NMDA receptors is mediated by 5-HT or NA
receptors.
We observed that the highest dose of intrathecal milnaci-
pran completely reversed thermal hyperalgesia induced by
NMDA. In contrast, desipramine and citalopram did not
produce any inhibitory effect, although the concentrations
of desipramine and citalopram in this study are sufficiently
high to inhibit reuptake of 5-HT or NA, respectively.
These results suggest that increases in 5-HT or NA alone
in the spinal cord have no effect on NMDA-induced ther-
mal hyperalgesia. The antagonistic action of milnacipran
for NMDA receptors may produce additional effects for
some types of chronic pain. Previous studies demonstrated
that intrathecal administration of milnacipran produced
antiallodynic effects in rats with peripheral nerve injury
[13,39,40], and that the effect was not completely reversed
by an α2 receptor antagonist or a 5-HT receptor antagonist
[13]. Therefore, it is conceivable that an antagonistic action
for NMDA receptors contributes to the antiallodynic effect
of milnacipran. Further studies are required to clarify the
molecular mechanisms underlying the inhibitory effect of
milnacipran on NMDA-mediated responses in dorsal horn
neurons. In addition, to elucidate whether the observed
effects were specific for milnacipran, further investigations
using another SNRI are necessary to resolve this question.
ERK activation is detected in the spinal dorsal horn neu-
rons after stimulation of nociceptive primary afferents and
contributes to the development of central sensitization
[22]. Activation of the NMDA receptor is partly involved
in ERK induction following nociceptive stimulation [22].
Analgesic drugs such as local anesthetics [41], opioids, or
cannabinoids [42] inhibit ERK induction in the spinal cord.
In the present study, we demonstrated that milnacipran
inhibited ERK induction following application of NMDA
in the spinal cord. This result is consistent with our behav-
ioral data showing that milnacipran attenuated thermal
hyperalgesia following intrathecal NMDA injection. Our
electrophysiological data clearly indicate that the direct
inhibitory effect of milnacipran on NMDA-mediated
current underlies these phenomena.
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antagonistic effect of NMDA receptors in the spinal
cord when administered intrathecally. However, it is
not clear whether milnacipran has the similar effect in
other central and peripheral tissue such as brain and
skin. Moreover, NMDA receptor antagonists such as
ketamine and phencyclidine have psychotomimetic or
anti-depressant properties in humans when adminis-
tered systemically. There have been no studies demon-
strating that milnacipran has these similar properties in
humans. Therefore, further study is required to clarify
this point.
NMDA glutamate receptors are one of the major re-
ceptor channel types mediating rapid excitatory neuro-
transmission in the central nervous system. This
receptor is composed of subunits from at least two fam-
ilies, NR1 and NR2. The NR1 subunit is essential for the
function of NMDA receptors and is ubiquitously
expressed in most neurons. The functional properties of
NMDA receptors are determined by the NR2 subunit
composition (NR2A–2D). Previous reports have demon-
strated that desipramine inhibited NMDA-evoked
responses in hippocampal neurons [32,43], but not in the
present study. The respective NR2 subunits show different
expression patterns in various regions of the brain and
spinal cord. Whereas NR2A and NR2B subunits are prom-
inent in the hippocampus [44], these subunits are not
identified in spinal dorsal horn neurons [45]. This different
composition of NMDA receptors may underlie the vari-
ability among tissues in the effects of desipramine on
NMDA receptor-responses.
NMDA glutamate receptors also play a key role in cen-
tral sensitization in chronic pain [3,4]. The pursuit of an
NMDA receptor antagonist for the relief of chronic pain
dates from the late 1980s when it was shown that NMDA
antagonists inhibit the “wind-up” response [46,47]. The
central sensitization that occurs in the spinal dorsal horn
is held to be an important event in the pathway leading to
neuropathic pain. For this reason, ketamine is currently
widely applied in the treatment of neuropathic pain and
for some kinds of chronic pain, including fibromyalgia
[48]. Although there is little evidence that NMDA receptor
antagonism is involved in the antinociceptive effect of mil-
nacipran, milnacipran has been widely used in patients
with fibromyalgia and has provided them with pain relief
[49,50]. These effects of milnacipran for chronic pain have
been previously discussed from the perspective of one as-
pect: balanced inhibition of the reuptake of 5-HT and NA.
However, in the present study, our data suggest that mil-
nacipran not only inhibits 5-HTand NA reuptake, but also
acts as an NMDA receptor antagonist. Milnacipran may
have the potential to prevent or suppress chronic pain
related to central sensitization, especially when injected
into intrathecal or epidural space.Conclusions
In conclusion, the present study suggests that milnaci-
pran, but not citalopram and desipramine, inhibits
NMDA-induced glutamatergic transmission in rat dorsal
horn neurons. These results suggest that not only is in-
hibition of 5-HT and NA reuptake an important factor
for the analgesia induced by milnacipran in the spinal
cord, but that inhibition of glutamate NMDA receptors
is critical as well.
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